Om Megashree Pharmaceuticals Posts Stable Growth in Q4, Profit Margins Decline Slightly

Om Megashree Pharmaceuticals Limited (OMPL) has released its audited financial results for the fourth quarter of FY 2024/25, showing steady growth in revenue but relatively modest profitability compared to its market valuation.

The company reported a total revenue of Rs. 277.96 million in Q4, up from Rs. 215.11 million in Q3 and Rs. 136.15 million in Q2, reflecting a continuous improvement in sales performance throughout the year. Gross profit for the quarter stood at Rs. 179.81 million, maintaining strong efficiency despite a decline in margin from 87.09% in Q2 to 64.69% in Q4.

Net income in Q4 was recorded at Rs. 8.92 million, slightly higher than Rs. 7.56 million in Q3, but with net profit margins hovering around a low 3–3.5% range. The company’s annualized earnings per share (EPS) stood at Rs. 1.49 in Q4, declining from Rs. 1.97 in Q2, reflecting weaker profitability growth relative to revenue expansion.

Despite its modest earnings, OMPL’s shares are trading at a steep price of Rs. 1,517.76 per share in the secondary market, giving it an extremely high reported price-to-earnings (PE) ratio of 1,019.96. The book value per share, in contrast, is only Rs. 103.94, highlighting a large premium investors are paying for the stock. The company has not announced any dividend distribution so far.